All News

Genentech has announced the results of a Phase III study which showed that atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) increased overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC).

Officials from the FDA have cleared an investigational new drug (IND) application for BW-1010 (BlueWillow Biologics), according to the company. The drug would be the company’s next-generation anthrax vaccine candidate.

Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.

The influenza A virus remains contagious in wet mucus from infected patients, even after being exposed to an ethanol-based disinfectant.

McKesson’s Health Mart has announced a partnership with Amazon Hub Counter pickup points, offering customers more convenient delivery options.

Top news of the day from across the health care landscape.

Patients with metastatic breast cancer who receive care aligned with National Comprehensive Cancer Network guidelines experienced less financial burden than patients who received guideline-discordant treatment.

According to the 2018 National Survey on Drug Use and Health, 9.9 million Americans misused controlled prescription drugs. On October 26, 2019 health care organizations across the country are participating in National Prescription Drug Take Back Day to help address this public safety and public health issue.

Niraparib (Zejula) received approval for patients with advanced homologous recombination deficiency-positive status ovarian cancer who have received 3 or more prior chemotherapies.

Bemcentinib is being evaluated as a treatment for elderly patients with acute myeloid leukemia whose disease has relapsed.

Top news of the day from across the health care landscape.

In addition to Jennifer Garner, actresses Julia Louis-Dreyfus and Christina Applegate are advocates for breast cancer, both being survivors of the disease.

Starting on October 21st, aclidinium bromide and formoterol fumarate (DUAKLIR PRESSAIR, Circassia) will be available for the maintenance treatment of patients with COPD.

The American Society of Health-System Pharmacists (ASHP) has awarded Scott J. Knoer, Pharm.D., M.S., FASHP, with its John W. Webb Lecture Award.

The high cost of treating blood cancer may contribute to delayed initiation of active treatment in newly-diagnosed Medicare beneficiaries.

Researchers note that a metabolic imbalance in some patients with cancer following treatment with nivolumab is associated with shorter survival.

Officials from the FDA have expanded the label of insulin aspart injection pumps, 100 u/mL (Fiasp, Novo Nordisk) to include use in insulin infusion pumps.

One in 8 pharmacies closed from 2009 to 2015, despite an overall increase in the number of pharmacies during this time.

Pegilodecakin in combination with pembrolizumab and nivolumab achieved measurable responses in patients with non-small cell lung cancer and kidney cancer.

The new, standardized, ready-to-use formulation of phenylephrine HCl can help reduce medication errors and improve patient safety.

Top news of the day from across the health care landscape.

Trial finds that the addition of anti-HIV immune globulin to standard of care patients with influenza B had a significant virological benefit.

According to investigators at the National Institutes of Health, a single dose of highly diluted VSV-Ebola virus (EBOV) vaccine is still protective against the disease.

Elexacaftor/ivacaftor/tezacaftor (Trikafta, Vertex Pharmaceuticals) is indicated for patients aged 12 years and older with cystic fibrosis who have at least 1 F508del mutation.

Ustekinumab both induced and maintained clinical remission in a significantly greater proportion of adult patients with moderately to severely active ulcerative colitis compared with placebo.

Top news of the day from across the health care landscape.

Research explores why patients with mutated KRAS genes in tumor cells are sensitive to cetuximab.

Minocycline topical foam, 4% is indicated for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in adults and pediatric patients aged 9 years and older